Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479961 | 0.94 | MAPT (0.49) | MAPTTP53LMNA | |
| SCHEMBL4485637 | 0.90 | PRMT1 (0.50) | MAPTRAB9ANPC1TP53LMNA | |
| SCHEMBL13864936 | 0.89 | MAPT (0.46) | MAPTRAB9ANPC1TP53LMNA | |
| SCHEMBL4476438 | 0.88 | TRPV1 (0.52) | MAPTRAB9ANPC1TP53LMNA | |
| SCHEMBL4468017 | 0.84 | PRMT1 (0.52) | MAPTRAB9ANPC1TP53LMNA | |
| SCHEMBL4491823 | 0.82 | LMNA (0.51) | RAB9ANPC1LMNAHTTSMN1; SMN2 | |
| SCHEMBL4486824 | 0.82 | PRMT1 (0.51) | MAPTRAB9ANPC1TP53LMNA | |
| SCHEMBL4477612 | 0.80 | LMNA (0.52) | LMNAHTTSMN1; SMN2 | |
| SCHEMBL4474531 | 0.77 | PRMT1 (0.51) | MAPTRAB9ANPC1TP53LMNA | |
| SCHEMBL4480191 | 0.77 | LMNA (0.55) | LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534804-B2 | Benzoxazole inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-19 | — | — | US | claimed |
| US-20070049628-A1 | Benzoxazole inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | claimed |
| US-7534804-B2 | Benzoxazole inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-19 | — | — | US | disclosed |
| US-20070049628-A1 | Benzoxazole inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049628-A1 | Benzoxazole inhibitors of 15-lipoxygenase | ALOX15, ALOX5, ALOX15B | MAPT 4438/4885RAB9A 4142/4885NPC1 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.